Background No consensus has been reached regarding the treatment order and timing of
epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and cytotoxic …

The epidermal growth factor receptor (EGFR) mutation is the first recognized molecular
target in non-small cell lung cancer that makes personalized therapy feasible. This …

Non-small-cell lung cancer (NSCLC) is the leading cause of cancer-related deaths. In the
last decade the EGF receptor (EGFR) signaling pathway has emerged as one of the most …

Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …

Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

INTRODUCTION: Erlotinib and gefitinib are tyrosine kinase (TK) inhibitors of epidermal
growth factor receptor (EGFR) that are effective in treating non-small cell lung cancer …

Background Several clinical trials showed that erlotinib was effective after the failure of
gefitinib in advanced non-small cell lung cancer (NSCLC). The aim of this study was to …

Background: Gefitinib and erlotinib, small-molecule kinase inhibitors that block epidermal
growth factor receptor (EGFR) signaling, have demonstrated a dramatic response rate and …

Purpose The aim of this study was to evaluate tumour response, QoL and adverse effects of
erlotinib, EGFR tyrosine kinase inhibitor (TKI), as a second line therapy for patients with …

Introduction Erlotinib is an effective treatment option for EGFR-mutant non-small cell lung
cancer. It is important to predict patients who will respond better to erlotinib. We designed …